JP6387669B2 - アゾール誘導体を含有する医薬 - Google Patents
アゾール誘導体を含有する医薬 Download PDFInfo
- Publication number
- JP6387669B2 JP6387669B2 JP2014089687A JP2014089687A JP6387669B2 JP 6387669 B2 JP6387669 B2 JP 6387669B2 JP 2014089687 A JP2014089687 A JP 2014089687A JP 2014089687 A JP2014089687 A JP 2014089687A JP 6387669 B2 JP6387669 B2 JP 6387669B2
- Authority
- JP
- Japan
- Prior art keywords
- reference example
- compound
- formula
- acetamide
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(N1CC(N*)=O)=CN(C)C1=O Chemical compound CC(N1CC(N*)=O)=CN(C)C1=O 0.000 description 6
- UWSNGPWBUJQFHW-JGNXYDOFSA-N C/C1=C/C/C=C\C(\NCC=O)=C/C=C1 Chemical compound C/C1=C/C/C=C\C(\NCC=O)=C/C=C1 UWSNGPWBUJQFHW-JGNXYDOFSA-N 0.000 description 1
- XPHWTMJWVRVKQE-UHFFFAOYSA-N CC(C)NC(CN(C(c1cccc(Cl)c1)=CN1c2ccc(C=C)cc2)C1=O)=O Chemical compound CC(C)NC(CN(C(c1cccc(Cl)c1)=CN1c2ccc(C=C)cc2)C1=O)=O XPHWTMJWVRVKQE-UHFFFAOYSA-N 0.000 description 1
- MZKUFCSGIKAAKE-UHFFFAOYSA-N CC(C)NC(CN(C(c1cccc(Cl)c1)=CN1c2ccc(CCO)cc2)C1=O)=O Chemical compound CC(C)NC(CN(C(c1cccc(Cl)c1)=CN1c2ccc(CCO)cc2)C1=O)=O MZKUFCSGIKAAKE-UHFFFAOYSA-N 0.000 description 1
- ONOHJQOZNZTXFS-UHFFFAOYSA-N CC(C)NC(C[n](c(-c1cc(Cl)ccc1)n1)nc1Br)=O Chemical compound CC(C)NC(C[n](c(-c1cc(Cl)ccc1)n1)nc1Br)=O ONOHJQOZNZTXFS-UHFFFAOYSA-N 0.000 description 1
- ORDFLKAATNVCCR-UHFFFAOYSA-N CC(C)NC(C[n](c(-c1cc(OC)ccc1)n1)nc1Br)=O Chemical compound CC(C)NC(C[n](c(-c1cc(OC)ccc1)n1)nc1Br)=O ORDFLKAATNVCCR-UHFFFAOYSA-N 0.000 description 1
- UTYIKEPPISRDDB-UHFFFAOYSA-N CC(C)NC(C[n]1c(-c(cc2)cc(Cl)c2F)nc(-c2ccc(CCN3CCOCC3)cc2)c1)=O Chemical compound CC(C)NC(C[n]1c(-c(cc2)cc(Cl)c2F)nc(-c2ccc(CCN3CCOCC3)cc2)c1)=O UTYIKEPPISRDDB-UHFFFAOYSA-N 0.000 description 1
- PHOVWIZOIXRUQI-UHFFFAOYSA-N CC(C)NC(C[n]1c(-c(cc2)cc(OC)c2F)nc(-c2ccc(CCN3CC(C)CC3)cc2)c1)=O Chemical compound CC(C)NC(C[n]1c(-c(cc2)cc(OC)c2F)nc(-c2ccc(CCN3CC(C)CC3)cc2)c1)=O PHOVWIZOIXRUQI-UHFFFAOYSA-N 0.000 description 1
- ILUWCZJNMZPGME-UHFFFAOYSA-N CC(C)NC(C[n]1c(-c(cc2)cc(OC)c2F)nc(-c2ccc(CCN3CCCCC3)cc2)c1)=O Chemical compound CC(C)NC(C[n]1c(-c(cc2)cc(OC)c2F)nc(-c2ccc(CCN3CCCCC3)cc2)c1)=O ILUWCZJNMZPGME-UHFFFAOYSA-N 0.000 description 1
- WQXAPHFLCGDCDW-UHFFFAOYSA-N CC(C)NC(C[n]1c(-c2cc(Cl)ccc2)nc(-c2ccc(CCN3CC(CO)CC3)cc2)c1)=O Chemical compound CC(C)NC(C[n]1c(-c2cc(Cl)ccc2)nc(-c2ccc(CCN3CC(CO)CC3)cc2)c1)=O WQXAPHFLCGDCDW-UHFFFAOYSA-N 0.000 description 1
- LDJFCFFGBYRZLK-UHFFFAOYSA-N CC(C)NC(C[n]1c(-c2cc(OC)ccc2)nc(Br)c1Br)=O Chemical compound CC(C)NC(C[n]1c(-c2cc(OC)ccc2)nc(Br)c1Br)=O LDJFCFFGBYRZLK-UHFFFAOYSA-N 0.000 description 1
- SSXVRNLGDJEHCG-UHFFFAOYSA-N CC(C)NC(C[n]1c(-c2nc(OC)ccc2)nc(-c2ccc(CCN3CCOCC3)cc2)c1)=O Chemical compound CC(C)NC(C[n]1c(-c2nc(OC)ccc2)nc(-c2ccc(CCN3CCOCC3)cc2)c1)=O SSXVRNLGDJEHCG-UHFFFAOYSA-N 0.000 description 1
- CLGIMSAUPVIXFW-UHFFFAOYSA-N CC(C)NC(Cc([o]c(-c(cc1)ccc1I)c1C)c1-c1cc(Cl)ccc1)=O Chemical compound CC(C)NC(Cc([o]c(-c(cc1)ccc1I)c1C)c1-c1cc(Cl)ccc1)=O CLGIMSAUPVIXFW-UHFFFAOYSA-N 0.000 description 1
- PLKUTMAMRPYGHW-UHFFFAOYSA-N CC(C)NC(Cc(c(-c1cccc(Cl)c1)c1)n[n]1-c1ccc(CCO)cc1)=O Chemical compound CC(C)NC(Cc(c(-c1cccc(Cl)c1)c1)n[n]1-c1ccc(CCO)cc1)=O PLKUTMAMRPYGHW-UHFFFAOYSA-N 0.000 description 1
- BNGWHVFGSIHYFS-UHFFFAOYSA-N CC(C)NC(Cc1c(-c2cccc(Cl)c2)[o]c(-c2ccc(CCO)cc2)n1)=O Chemical compound CC(C)NC(Cc1c(-c2cccc(Cl)c2)[o]c(-c2ccc(CCO)cc2)n1)=O BNGWHVFGSIHYFS-UHFFFAOYSA-N 0.000 description 1
- WEDSCXYVIXJZJD-UHFFFAOYSA-N CC(C)NC(Cc1c(-c2cccc(Cl)c2)[s]c(-c2ccc(CCO)cc2)n1)=O Chemical compound CC(C)NC(Cc1c(-c2cccc(Cl)c2)[s]c(-c2ccc(CCO)cc2)n1)=O WEDSCXYVIXJZJD-UHFFFAOYSA-N 0.000 description 1
- UFXCDCKGQZJABE-UHFFFAOYSA-N CC(C)NC(Cc1c[n](-c2ccc(C=C)cc2)nc1-c1cccc(Cl)c1)=O Chemical compound CC(C)NC(Cc1c[n](-c2ccc(C=C)cc2)nc1-c1cccc(Cl)c1)=O UFXCDCKGQZJABE-UHFFFAOYSA-N 0.000 description 1
- FKRDWMCSESIFCV-UHFFFAOYSA-N CC(C)NC(Cc1cc(-c(cc2)ccc2OS(C(F)(F)F)(=O)=O)n[n]1-c1cccc(Cl)c1)=O Chemical compound CC(C)NC(Cc1cc(-c(cc2)ccc2OS(C(F)(F)F)(=O)=O)n[n]1-c1cccc(Cl)c1)=O FKRDWMCSESIFCV-UHFFFAOYSA-N 0.000 description 1
- JTDRTFLAROWDTE-UHFFFAOYSA-N CC(Cc(cc1)cnc1Cl)N1C2COCC1CC2 Chemical compound CC(Cc(cc1)cnc1Cl)N1C2COCC1CC2 JTDRTFLAROWDTE-UHFFFAOYSA-N 0.000 description 1
- VAFKUXUJCXXWGN-UHFFFAOYSA-N CCOC(CC(NNC(Nc1cc(Cl)ccc1)=O)=O)=O Chemical compound CCOC(CC(NNC(Nc1cc(Cl)ccc1)=O)=O)=O VAFKUXUJCXXWGN-UHFFFAOYSA-N 0.000 description 1
- PSEJFWRPEJWCJQ-UHFFFAOYSA-N COc1c(CCN2C3COCC2CC3)ccc(Br)c1 Chemical compound COc1c(CCN2C3COCC2CC3)ccc(Br)c1 PSEJFWRPEJWCJQ-UHFFFAOYSA-N 0.000 description 1
- OURAIJQJOBCPRE-UHFFFAOYSA-N COc1cc(CCN2CCOCC2)ccn1 Chemical compound COc1cc(CCN2CCOCC2)ccn1 OURAIJQJOBCPRE-UHFFFAOYSA-N 0.000 description 1
- YRXOKZWINNXPCP-UHFFFAOYSA-N Clc1ncc(CCN2CCOCC2)cc1 Chemical compound Clc1ncc(CCN2CCOCC2)cc1 YRXOKZWINNXPCP-UHFFFAOYSA-N 0.000 description 1
- QROLVEGOKPAEJV-UHFFFAOYSA-N Fc1c(CCN2C3COCC2CC3)ccc(Br)c1 Chemical compound Fc1c(CCN2C3COCC2CC3)ccc(Br)c1 QROLVEGOKPAEJV-UHFFFAOYSA-N 0.000 description 1
- WINDKVPQCLNLCA-UHFFFAOYSA-N O=C1NC(c2cc(Cl)ccc2)=CC1c(cc1)ccc1Br Chemical compound O=C1NC(c2cc(Cl)ccc2)=CC1c(cc1)ccc1Br WINDKVPQCLNLCA-UHFFFAOYSA-N 0.000 description 1
- HQQJTSLBKUZDSM-UHFFFAOYSA-N OCCc(cc1)ccc1N(C(C(CC(O)=O)=C1c2cccc(Cl)c2)=O)C1=O Chemical compound OCCc(cc1)ccc1N(C(C(CC(O)=O)=C1c2cccc(Cl)c2)=O)C1=O HQQJTSLBKUZDSM-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014089687A JP6387669B2 (ja) | 2013-04-26 | 2014-04-24 | アゾール誘導体を含有する医薬 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013093594 | 2013-04-26 | ||
| JP2013093594 | 2013-04-26 | ||
| JP2014089687A JP6387669B2 (ja) | 2013-04-26 | 2014-04-24 | アゾール誘導体を含有する医薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014224108A JP2014224108A (ja) | 2014-12-04 |
| JP2014224108A5 JP2014224108A5 (enExample) | 2017-06-08 |
| JP6387669B2 true JP6387669B2 (ja) | 2018-09-12 |
Family
ID=52123088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014089687A Expired - Fee Related JP6387669B2 (ja) | 2013-04-26 | 2014-04-24 | アゾール誘導体を含有する医薬 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6387669B2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019012822A2 (pt) | 2016-12-22 | 2019-11-26 | Bayer Ag | 1,2,4-tiadiazolilpirrolonas e 1,2,4-tiadiazolil-hidantoínas e sais das mesmas e uso das mesmas como herbicidas |
| JP2020504115A (ja) | 2016-12-22 | 2020-02-06 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 置換アゾリルピロロンおよびアゾリルヒダントインならびにその塩ならびに除草活性物質としてのその使用 |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| PH12022552373A1 (en) * | 2020-03-17 | 2023-12-18 | Sumitomo Pharma Co Ltd | Oxadiazole derivative |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000063363A (ja) * | 1998-08-12 | 2000-02-29 | Yamanouchi Pharmaceut Co Ltd | 新規なトリアゾール誘導体 |
| US8350043B2 (en) * | 2005-06-07 | 2013-01-08 | Pharmacopeia, Inc. | Azinone and diazinone V3 inhibitors for depression and stress disorders |
| DE102006024024A1 (de) * | 2006-05-23 | 2007-11-29 | Bayer Healthcare Aktiengesellschaft | Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung |
| JP2010229035A (ja) * | 2007-08-01 | 2010-10-14 | Taisho Pharmaceutical Co Ltd | ピリドピリミジン−４−オン誘導体 |
| WO2009130232A1 (en) * | 2008-04-24 | 2009-10-29 | Glaxo Group Limited | Pyrazolo [1, 5 -a] pyrazine derivatives as antagonists of v1b receptors |
| JP5369721B2 (ja) * | 2009-01-30 | 2013-12-18 | 大正製薬株式会社 | ピリドピリミジン−４−オン誘導体 |
| WO2011104322A1 (de) * | 2010-02-27 | 2011-09-01 | Bayer Pharma Aktiengesellschaft | Bis-arylverknüpfte aryltriazolone und ihre verwendung |
| BR112013007389B1 (pt) * | 2010-10-01 | 2022-03-22 | Taisho Pharmaceutical Co., Ltd | Derivado de 1,2,4-triazolona, substância e composição farmacêutica |
| EP2772482B1 (en) * | 2011-10-27 | 2016-03-09 | Taisho Pharmaceutical Co., Ltd. | Azole derivative |
-
2014
- 2014-04-24 JP JP2014089687A patent/JP6387669B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014224108A (ja) | 2014-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6025066B2 (ja) | アゾール誘導体 | |
| JP6424219B2 (ja) | 複素芳香環−ベンジル−アミド−サイクルコアを含むオートタキシン阻害剤 | |
| JP6995109B2 (ja) | ジメトキシフェニル置換インドール化合物 | |
| AU2016279388B2 (en) | NRF2 regulators | |
| AU2018243691B2 (en) | Heterocyclic compound | |
| JP6647592B2 (ja) | ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用 | |
| AU2013207252A1 (en) | Carbamate compounds and pharmaceutical compositions thereof | |
| JP6356790B2 (ja) | 新規ｃｙｐ１７阻害剤／抗アンドロゲン | |
| TW202309010A (zh) | 新穎雜環化合物 | |
| WO2009009411A1 (en) | Substituted heterocyclic ethers and their use in cns disorders | |
| JP6387669B2 (ja) | アゾール誘導体を含有する医薬 | |
| JP2023513373A (ja) | Ｐ２ｘ３修飾薬 | |
| HK1195056B (en) | Azole derivative | |
| HK1195056A (en) | Azole derivative | |
| WO2018109271A1 (en) | New bromodomain inhibitors | |
| NZ623918B2 (en) | Azole derivative | |
| JP2025525350A (ja) | Ｍａｇｌ阻害剤としての新規複素環－カルボニル－環式化合物 | |
| BR112017027132B1 (pt) | Composto regulador do nrf2, composição farmacêutica compreendendo o dito composto e uso do mesmo para o tratamento de transtornos associados com a regulação de nrf2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170420 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170420 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20171219 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180215 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180717 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180730 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6387669 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |